expand_moreexpand_lessexpand_moreexpand_less
|
 |
Sudeshna RayThe Ken |
India’s fourth-largest drugmaker lost two of its most-profitable drugs within months. Its new pipeline is what investors care about
Factory-less HRV Pharma has turned managing regulatory paperwork into a successful standalone business
Hospitals and stockists are making steep margins off initiatives meant to make life-saving medication affordable
Reliance on pre-existing tech and a dearth of data dim Cent’s otherwise laudable goal of AI-aided early detection
As Novo prepares to lose market exclusivity in India, it sets its sights on the healthcare system, partnering with Healthifyme, buying hospitals, and...
login
who are we?
contact us
qosheapp
